Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Joan H. Schiller, David Harrington, Chandra P. Belani et al. · New England Journal of Medicine · 2002 · 5K citations

Medicine, Oncology, Pharmacology +7

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

J Oan H. S Chiller, D Avid H Arrington, C Handra P. B Elani et al. · 2002 · 3.7K citations

Medicine, Oncology, Pharmacology +11

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

Reginald V. Lord, Jan Brabender, David R. Gandara et al. · PubMed · 2002 · 671 citations

Medicine, Molecular Biology, Oncology +14

<i>ERCC1</i> and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy

Yoshinori Shirota, Jan Stoehlmacher, Jan Brabender et al. · Journal of Clinical Oncology · 2001 · 609 citations

Medicine, Oncology, Pharmacology +16

Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.

M R Spitz, Xueyan Wu, Ying Wang et al. · PubMed · 2001 · 493 citations

Life Sciences, Genetics, Molecular Genetics +15